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Purpose: Little is known about the relationship between the financial burden of cancer and the 
physical and emotional health of cancer survivors. We examined the association between 
financial problems caused by cancer and reported quality of life in two samples of cancer patients.  
 
Patients and Methods: Data from the 2010 National Health Interview Survey (NHIS) were 
analyzed. A multivariate regression model was used to examine the relationship between the 
degree to which cancer caused financial problems and the patients' reported quality of life. 
In a separate study, a cross-sectional survey was administered at a large academic breast 
center.  Patients who had received a diagnosis of breast cancer between 6 and 18 months prior 
were eligible. Patients who qualified were invited to complete a survey including 
sociodemographic factors, and questions pertaining to their perceived quality of life and the 
financial burden of their cancer treatment.  These data were correlated with tumor and treatment 
factors.  Non-parametric statistical analyses were conducted using SPSS. 
Results:   In the NHIS data, of 2108 cancer patients who answered the survey question, "To what 
degree has cancer caused financial problems for you and your family?”, 8.6% reported “a lot", 
while 69.6% reported “not at all”. Patients reporting "a lot" of financial problems due to cancer 
were more likely to rate their physical health (18.6% vs. 4.3%, p<0.001), mental health (8.3% vs. 
1.8%, p<0.001), and satisfaction with social activities and relationships (11.8% vs. 3.6%, 
p<0.001) to be poor compared to those with no financial hardship.  On multivariate analysis 
controlling for all of the significant covariates on bivariate analysis, the degree to which cancer 
caused financial problems was the strongest independent predictor of quality of life. Patients who 
reported that cancer caused "a lot" of financial problems were four times less likely to rate their 
quality of life as "excellent", "very good", or "good" (OR=0.24; 95% CI: 0.14-0.40, p<0.001).   
 
In the Yale Breast Center study, a total of 72 patients completed the survey.  The mean age was 
60 and mean tumor size was 2.3cm. When asked to what degree cancer caused financial 
problems, 18.1% responded “a lot”, 12.5% “some”, 18.1% “a little”, and 44.4% “not at all”. The 
majority (84.7%) self-reported their QOL to be “excellent”, “very good”, or “good”, while 8.4% 
answered “fair” or “poor”. On bivariate analysis, insurance status (p=0.029), education (p=0.013), 
family income (p=0.029), treatment history (chemotherapy, endocrine therapy, neither, or both) 
(p<0.001), and ER receptor status (p=0.037) were all significantly associated with the degree to 
which cancer caused financial problems.  
 
Conclusion:   Increased financial burden due to cancer was the strongest independent predictor of 
poor quality of life among cancer survivors in a nationwide population-based survey. We studied 
this relationship in a population of breast cancer patients at an academic center. Patients with 
hormone receptor-negative disease were more likely to report a large degree of financial 
problems. These patients represent a subset of patients with a poorer prognosis requiring more 
intensive therapy, These data support the need for increased clinician awareness of financial 
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Contributors to Financial Distress in Cancer Patients 
For a patient who receives a diagnosis of cancer, the financial impact of this diagnosis 
can be significant. The magnitude of the resulting financial burden is determined by a 
multitude of factors, including household income, socioeconomic status, insurance status, 
and extent of disease. Causes of cancer-related financial stress are multifactorial. 
Treatment-related costs can be substantial, including costs of chemotherapy, radiation, 
and surgery, as well as home health care and travel to treatment centers (1). Patients who 
are employed may experience loss of productivity at work or total loss of employment 
and work-related benefits (2, 3). Household finances may suffer if the patient’s family 
members take time away from work to help with their care (4). Other less apparent causes 
of financial burden include child care, domestic help, medical equipment, special foods, 
and nutritional supplements (1).  In one cross-sectional survey sampling cancer patients 
in a region of the UK, costs of oil and heating, costs of food, and loss of income were the 
most frequently cited contributors to the financial impact of their disease (5). 
 
Magnitude and Drivers of Cost of Cancer Treatment 
Spending on cancer treatment has increased substantially during recent years, with more 
than a two-fold increase of direct medical costs relating to cancer treatment between the 
years of 1990 and 2008, after adjustment for inflation (6). Without taking into account the 
increase in expensive novel therapeutics, a projected growth in the population of elderly 
Americans will likely drive costs of cancer care in the upcoming years. Using data from 
the SEER database and assuming constant incidence, survival and cost, Mariotto et al 
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projected that the number of cancer survivors will increase by 4.3 million (31 percent) 
and yearly costs of cancer care would increase from 124.57 to 157.77 billion 2010 USD 
(27 percent) between 2010 and 2020 (7).   
 
Most costs of cancer treatment billed to Medicare come during the first year after a 
cancer diagnosis; in the case of colorectal cancer, diagnoses of Stage II and III disease 
have the highest long-term aggregate cost billed to Medicare (8). Between 1991 and 2002, 
the cost of treatment for breast, lung, and colorectal cancer billed to Medicare increased 
after adjustments for inflation; the bulk of this increase was attributable to an increase in 
rates of surgical intervention, an increase in the rate of adjuvant therapy, and an increase 
in the cost of this treatment (9).  Costs of cancer care in America continue to rise in this 
decade due to a variety of concurrent processes, including an increase in the elderly 
population, overutilization of therapy, and an increase the number of expensive 
innovative therapies available, with a proportion of these costs passed on to the patient 
(10). 
 
Effects of Financial Burden 
A high proportion of patients are affected economically by a cancer diagnosis. The 
SUPPORT study found that roughly one-third of families of seriously ill patients reported 
losing most or all of their family’s savings (11). Ramsey et al. found in an analysis of 
patients in Washington state that cancer patients were 2.65 times more likely to file for 
bankruptcy in comparison with patients without a diagnosis of cancer (12).  
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Among American cancer patients, the degree of financial burden due to cancer can be 
variable. Low income patients have been shown to have disproportionately high expenses 
due to cancer (13). Insurance coverage can also affect an individual’s cancer-related 
economic burden, with Medicare patients having more comorbidities but half the monthly 
expenditures of commercially insured patients in one study (14). Additionally, younger 
patients are more likely to experience financial distress. In the aforementioned study by 
Ramsey et al., younger patients had two to five times higher rates of bankruptcy when 
compared to cancer patients age 65 or older (12). Despite this finding, elderly patients are 
also affected. Cancer patients over the age of 70 are significantly more likely to have 
increased out-of-pocket expenditures for medical care in comparison with their cancer-
free counterparts; the largest contributors to this increase in OOP expense comes in the 
form of prescription medications and home care services (15). Depending on an 
individual’s particular financial and personal circumstances, the economic toll of cancer 
can be profound. 
 
Financial problems related to cancer can adversely affect patients’ compliance with 
treatment and access to care and, consequently, their future physical health. When 
analyzing NHIS data from 2003-2006, Weaver et al. found that patients with cancer were 
more likely than those without cancer to delay or forgo medical care (16). Through 
analysis of data found in the 2010 NHIS Cancer Supplement, Kent et al. found patients 
specifically reporting any degree of cancer-related financial problems were more likely to 
delay or forego medical care, including prescription medications, after adjusting for 
covariates (17). For example, among patients that were recently prescribed oral 
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oncolytics, those who were enrolled in pharmacy plans with a higher degree of cost-
sharing were more likely to abandon therapy compared to those with plans requiring less 
cost-sharing (18).  
 
Some patients experiencing financial distress will subsequently make financial decisions 
that have a substantial impact on the lives of themselves and their family. Among insured 
patients contacting a prescription drug assistance program, for example, 46% reported 
decreasing their amount of spending on food and clothing and 46% reported using a 
portion of their financial savings to defray costs of treatment (19). In a qualitative study 
of Irish cancer patients, patients also cited cutting back on food shopping and clothes 
shopping, in addition to reducing heat in their homes, and forgoing future medical 
treatment (20). 
 
Financial Burden of Breast Cancer 
The financial effects of a breast cancer diagnosis can be long-lasting. When assessing 
QOL in breast cancer survivors at an average of 12.5 years postdiagnosis, Hsu et al. 
found that breast cancer patients had EORTC financial impact subscores 6.3% higher 
than cancer-free age-matched controls (21).  Similarly, when assessing long-term QOL 
longitudinally in breast cancer survivors in a region of Germany, Koch et al. found that 
reported financial difficulties for breast cancer survivors were significantly higher than 
those seen in controls, and even increased from year five to year ten post-diagnosis (22).  
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Financial burden can affect behavior in breast cancer patients. In a retrospective cohort 
study examining patients over 50 with resected breast cancer using mail-order 
prescriptions for aromatase inhibitors, higher prescription co-payments were significantly 
associated with nonpersistence and nonadherence to AI therapy, with this effect more 
pronounced in older women (23).  
 
Instruments to Measure QOL 
The financial burden of a cancer diagnosis may affect quality of life both on an 
immediate and long-term basis. Investigators interested in this outcome measure have 
available a variety of different methods for assessing quality of life. In a 
multidimensional model of health, physical, social, and mental components play a role 
along with morbidity and mortality. The World Health Organization (WHO) has defined 
quality of life as:  
…the individual’s perception of their position in life in the context of the culture 
and value systems in which they live and in relationship to their goals, 
expectations, standards, and concerns. It is a broad ranging concept affected in a 
complex way by a person’s physical health, psychological state, level of 
independence and their relationships to salient features of their environment (24).  
 
Some investigators choose to narrow their focus to health-related quality of life (HR-
QOL); there are several validated instruments in use for measuring HR-QOL specifically 
in cancer patients. The European Organization for Research and Treatment of Cancer 
(EORTC) QLQ C-30 is a thirty item validated measure for quality of life in all cancer 
patients; it can be completed independently by patients and includes questions to assess 
physical, role, cognitive, emotional, and social functioning as well as global QOL (25). 
The QLQ-BR23 was designed as a breast cancer specific supplement to the QLQ C-30, 
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and assesses domains such as side effects from breast cancer, chemotherapy or radiation 
therapy, body image, and sexuality (26). 
 
Both instruments have been validated clinically and cross-culturally and provide 
standardized measures of QOL, which are especially useful in clinical trials. However, 
quality of life is influenced by individual attributes and preferences, while standardized 
QOL measures typically give the importance of each item the same weight across surveys. 
This observation has led some researchers to suggest that a global self-reported 
assessment of both overall QOL and health-related QOL is an essential component to any 
QOL measure, because self-reported QOL takes into account the values of the individual 
in a way that many QOL survey items do not (27, 28). 
 
Cancer-Related Financial Problems and QOL 
The psychosocial effects of cancer-related financial strain are understudied. The degree to 
which cancer-related financial burden affects an individual’s overall quality of life has 
not been commented on in the literature as frequently as numerical data on treatment 
costs. The subjective experience of cancer-related expenses, ie financial distress, can 
have an impact on a patient’s overall well-being and satisfaction with life. In a qualitative 
study of Irish cancer patients, patients cited a variety of emotional effects resulting from 
the cost of their disease, including worry about shielding their children and spouses from 
the financial effects of their disease and anxiety about having to ask for financial 
assistance (20). The emotional toll of unexpected monetary costs may have a significant 
impact on quality of life.  
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Several studies have recently emerged reporting an association between increased 
economic burden due to cancer and decreased quality of life (29). In one, Meneses et al., 
using the QOL-BCS and Breast Cancer Finances Survey (BCFS) in a population of 
patients taken from an ongoing clinical trial, found that economic hardship events such as 
changes in motivation, productivity, or attendance at work, were negatively associated 
with QOL compared to baseline at 3 and 6 month follow-up on multivariate analysis (30). 
In another, Sharp et al. studied patients more than 6 months after a cancer diagnosis using 
a nationwide database in Ireland and found a threefold increase in depression risk among 
patients reporting increased cancer-related financial stress and financial strain (29). In 
addition, Gupta et al. examined this relationship with a case series of patients at a single 
American treatment center using QLQ C-30 to quantify financial distress and QLI to 
measure quality of life; using multiple regression analysis, every 10 point increase in 
financial difficulty score was significantly associated with a decline in every QOL 
domain, including physical, social/economic, spiritual, family, and overall function (31). 
 
Taken together, these studies suggest a negative correlation between cancer-related 
financial problems and quality of life, including mental health. However, little has been 
published on this relationship in a nationwide sample of American cancer patients. 
Furthermore, there is a paucity of data on clinical factors that may impact this 




Statement of Purpose: 
The aims of this study were as follows: 
 
1. To characterize the relationship between cancer-related financial problems and 
self-reported quality of life through analysis of data from a nationwide 
population-based survey.  
2. To examine the relationship between cancer-related financial problems and 
self-reported quality of life in a population of breast cancer patients at a large 
academic center, and to further elucidate the impact of clinicopathologic and 




Aim #1: NHIS data 
Data from the 2010 National Health Interview Survey (NHIS) were analyzed. The NHIS 
is the largest source of health information of US households, designed to reflect the 
nation’s civilian noninstitutionalized population. It is a cross-sectional interview study 
administered annually by the National Center for Health Statistics (NCHS), Centers for 
Disease Control and Prevention. The NHIS uses a multistage sample design involving 
stratification and clustering techniques, and is designed to oversample Black, Hispanic, 
and Asian persons. The survey is administered face-to face by one of about 400 trained 
surveyors using computer assisted personal interviewing (CAPI), in which survey 
administrators enter data directly into a laptop computer at the time of interview. 
 
The core of the survey contains four different segments: Household, Family, Sample 
Adult, and Sample Child. The Household segment collects demographic information on 
all members of the household from a single representative. The Family segment verifies 
and collects additional demographic information about individual member of the 
household. A sample adult and sample child (if applicable) are randomly chosen from 
each household and questionnaires are administered to collect additional information on 
health status, health service utilization, and health behaviors. Supplements to the survey 
are administered to address specific public health questions. The Cancer Control 
Supplement (CCS) collects information on cancer-related health behaviors and cancer 
screening. On years when the CCS is administered, it is given to the sample adult in each 
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selected household. The CCS was last administered in 2010. Further data on the NHIS 
are available elsewhere (32). 
 
Respondents were asked if they had ever been told that they had cancer.  For those who 
were 18 years of age or older, and who responded affirmatively, they were subsequently 
asked “To what degree has cancer caused financial problems for you and your family?”.  
Possible responses were “a lot”, “some”, “a little”, “not at all”, “don’t know”, and 
“refused”.   
 
Data analysis 
We analyzed the resulting data. Bivariate analyses were performed to examine whether 
the respondents who refused to answer or answered “don’t know” to this question had 
statistically significant differences in their responses to other survey items examined in 
this study (Table 1). Those who answered the question informatively then formed the 
cohort of interest for our analyses. 
 
The degree to which cancer caused financial problems was then evaluated in terms of its 
correlation with sociodemographic covariates, including sex, age, race, highest level of 
education completed, insurance status, family income, region of residence, and cancer 
type (Table 2). In addition, we evaluated the effect of cancer-related financial problems 
on respondents’ perceived quality of life. In particular, respondents were asked to rate 
their quality of life in general, their physical health, their mental health, and their 
satisfaction with social activities and relationships. Possible responses included 
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“excellent, “very good”, “good”, “fair”, and “poor” (Table 3). Furthermore, we evaluated 
respondents’ perceived risk of recurrence (“What do you think the chances that your 
cancer will come back or get worse within the next 10 years?”), and their worry regarding 
the same (“How often do you worry that your cancer may come back or get worse?”, 
Table 4).  
 
A binary logistic regression model was created to determine the independent effect of 
cancer-related financial problems on quality of life, controlling for all of the 
sociodemographic factors found to be significant at p<0.1 on bivariate analysis (Table 5). 
All statistical analyses were performed with SUDAAN software (Release 9.0.1, Research 
Triangle Park, NC). 
 
Aim #2: Yale Breast Center data 
A survey study was conducted at the Breast Center at Smilow Cancer Hospital at Yale-
New Haven. Because clinicopathologic information was not available from the NHIS 
cohort and many patients in that study were long-term survivors, we wanted to evaluate 
the effect of cancer-related financial problems and QOL in a cohort of recently diagnosed 
breast cancer patients in whom tumor and treatment data were available.  
 
Patients attending follow-up appointments at the surgical oncology clinic who had 
received a diagnosis of breast cancer between 6 and 18 months prior were eligible. The 
survey items included questions about sociodemographic factors (age, race, marital status, 
education, sexual orientation, family income), financial problems due to cancer, 
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insurance status, out-of-pocket spending on medical expenses, and quality of life 
(including physical, mental, social, and overall QOL, as well as worry that cancer will 
return and self-reported chances of cancer returning or becoming worse), using language 
identical to the survey items included in the NHIS survey. An additional survey was 
given to the clinician, asking the clinician to report which type of surgery the patient had 
undergone and whether the patient had received treatment with conventional 
chemotherapy, radiation, trastuzumab, tamoxifen, or an aromatase inhibitor. Pathology 
reports for each patient were printed, deidentified, and attached to the survey document. 
 
Including a validated QOL instrument for cancer patients, such as the EORTC QLQ-C30 
or QLQ BR-23 for breast cancer specific QOL was considered. However, average length 
of time to complete QLQ BR-23 along with the QLQ-C30 is 9.2 minutes and it was felt 
that this addition to the length of time to complete the survey would be too onerous for 
patients, thus contributing to a decline in response rate (26). The outcome measure 
ultimately used was the answer to the survey item “In general, would you say your 
quality of life is…”, as was used in the prior analysis of NHIS data. 
 
Data analysis  
When answering the question about insurance coverage, some patients marked that they 
had coverage with both Medicare and private insurance. In these instances, private 
insurance was considered to the primary coverage for purposes of data analysis.  
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After obtaining data from pathology reports, cancer type was categorized as either 
invasive (e.g. infiltrating ductal carcinoma, infiltrating lobular carcinoma, invasive 
squamous cell carcinoma) or non-invasive (e.g. DCIS) for purposes of data analysis. 
 
Using clinician-provided data in the survey, a new “treatment history” variable was 
constructed. Patients were classified as having received systemic treatment (i.e. 
chemotherapy and/or trastuzumab) only, endocrine therapy (ie aromatase inhibitors or 
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Aim #1: NHIS Data 
For the 2010 administration of the NHIS, the final response rate for the adult Sample 
Adult was 60.8% (32). Among the 2151 adult cancer survivors surveyed (representing 
17,873,413 people in the population), 98.0% answered the question regarding the degree 
to which cancer caused them and their family financial problems. Among all people who 
were asked the question, 1.5% reported that they “didn’t know” how cancer had 
financially impacted them or declined to answer.  Comparing informative responders to 
those who responded “don’t know” or declined to answer, no statistically significant 
differences were seen in terms of sociodemographic factors, suggesting that there was 
unlikely to be a systematic reporting bias in those who responded to the question of how 
cancer affected their financial life (Table 1).  Those who refused to answer or didn’t 
know how cancer affected their financial status did, however, had a significantly lower 
rate of worrying about their cancer coming back than those who provided informative 
answers (0% vs. 9.6%, p=0.005).   
 
Of those who provided informative responses, 8.6% reported “a lot” of cancer-related 
financial problems, 11.7% reported “some”, 10.3% “a little”, and 69.6% “not at all”. On 
bivariate analysis, compared to respondents who answered “not at all”, respondents 
reporting “a lot” of financial problems were more likely to be female (63.5% vs. 55.9%, 
p=0.016), under the age of 65 (81.0% vs. 47.3%, p<0.001), of non-Caucasian race 
(18.8% vs. 7.4%, p<0.001), with less than a four-year college education (81.2% vs. 67.1, 
p=0.002), and a total combined household income of less than $35,000 (51.6% vs. 32.4%, 
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p<0.001); Table 2. Subjects who reported “a lot” of cancer-related financial problems 
were also less likely to report Medicare as their primary health insurer (32.9% vs. 54.4%, 
p<0.001).  The three types of cancer with the largest proportion of patients reporting “a 
lot” of financial problems were thyroid cancer (30.6%), ovarian cancer (25.3%), and lung 
cancer (23.7%) (p<0.001). Region of residence was not significantly correlated with 
degree of cancer-related financial problems (p=0.390).   
 
Bivariate analyses were then performed to examine the association between degree of 
cancer-related financial problems and subjective evaluation of quality of life (Table 3). 
Compared to patients who answered “not at all”, patients reporting “a lot” of cancer-
related financial problems were more likely to report “poor” quality of life (p<0.001). 
This was true for self-assessment of general quality of life, as well as respondents’ rating 
of their physical health, mental health, and social life. Additionally, patients reporting “a 
lot” of cancer-related financial problems were more likely to believe the chances of their 
cancer returning to be high and report a higher frequency of worry about their cancer 
returning in the future (p<0.001, Table 4).  
 
For the multivariate analysis, we created an dichotomous outcome variable for quality of 
life, in which we compared “good”, “very good”, or “excellent” vs. “fair” or “poor”. We 
found self-reported quality of life of “good” or better was inversely correlated with the 
degree to which cancer caused financial problems, independent of all sociodemographic 
variables found to be significant on bivariate analyses (Table 5).  Patients with “a lot” of 
cancer-related financial problems carried a four-fold decrease in likelihood of reporting a 
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quality of life of “good” or better (OR: 0.24; 95% CI 0.14-0.40, p<0.001). Age, education, 
insurance status, and total combined family income were also significant independent 
predictors of quality of life. 
 
Aim #2: Yale Breast Center Data 
A total of 72 patients completed the survey.  Of these, 5 respondents (6.9%) did not 
answer questions about quality of life and financial problems due to cancer. Clinician-
provided information about treatment history was absent from two surveys (2.8%).  
 
Of patients who responded, the mean age of respondents was 60.4 ± 12.3 years, with a 
median age of 61 years. Additional demographic information can be found in Table 6. In 
our sample, 42 (58.3%) had private insurance coverage, 16 (22.2%) had Medicare, 9 
(12.5%) had Medicaid, and 2 (2.8%) were uninsured.   
 
Clinicopathologic data is presented in Table 7. With regard to treatment history, the 
majority of patients had received a lumpectomy or partial mastectomy (n=44, 61.1%), 
with the rest having received a complete mastectomy. The majority had received 
radiation therapy (n=44, 61.1%). Less than half had received chemotherapy (n=29, 
40.3%), trastuzumab (n=8, 11.1%), tamoxifen (n=16, 22.2%), or an aromatase inhibitor 
(n=29, 40.3%). For the 47 patients with an invasive component to their disease, mean 
tumor size was 2.3 ± 1.9 cm. The majority of patients (n=39, 54.2%) had node-negative 
disease. Though not all patients had information about Her2/Neu and receptor status 
included in their pathology report, of the 35 who did, 94.3% of tumors were negative 
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Her2/Neu by FISH. Additionally, out of 53 patients for whom this information was 
available, 42 (79.2%) were positive for estrogen receptor (ER), and 40 (75.5%) were 
positive for progesterone receptor (PR).  
 
When asked to report out-of-pocket health-care related expenses over the last year, 22 
(30.6%) reported expenses of $500 or less whereas 12 (16.7%) reported expenses of 
$5,000 or more. When asked to what degree cancer caused financial problems, 13 
(18.1%) responded “a lot”, 9 (12.5%) “some”, 13 (18.1%) “a little”, and 32 (44.4%) “not 
at all”.  
 
On bivariate analysis, the degree of association between demographic variables and 
cancer-related financial problems was evaluated (Table 8). Financial problems were 
significantly associated with insurance status (p=0.029); a greater proportion of patients 
with “a lot” of financial problems reported Medicaid coverage (41.7% vs 6.3%) and a 
lower proportion reported private insurance coverage (33.3% vs. 65.6%) or Medicare 
coverage (8.3% vs. 28.1%) compared to those with no financial problems. Age (p<0.001), 
education level (p=0.013), and family income (p=0.029) were also significantly 
associated with the degree of reported financial problems. Out-of-pocket spending on 
medical care approached a significant association with the degree of cancer-related 




On analysis of data from pathology reports, degree of cancer-related financial problems 
was significantly associated with ER receptor status (p=0.037, Table 8).  A lower 
proportion of patients with “a lot” of cancer-related financial problems had ER-positive 
disease compared to those reporting none (44.4% vs. 84.0%). Cancer type (invasive vs. 
noninvasive, p=0.617), tumor size (p=0.650), tumor grade (p=0.103), node positivity 
(p=0.284), Her2/Neu FISH (p=0.480), PR status (p=0.150), and lymphovascular invasion 
(p=0.787) were all not significantly associated with financial distress.  
 
The degree to which cancer caused financial problems was significantly associated with 
treatment history (systemic treatment only vs. endocrine therapy only vs. both vs. neither, 
p<0.001). Among survey respondents who reported “a lot” of financial problems, 9 
(69.2%) had received systemic treatment only, 4 (30.8%) had received neither systemic 
nor endocrine treatment. No patients who had received endocrine treatment only or both 
types of treatment reported “a lot” of problems. 
 
Surgery type approached significance (p=0.050), with patients reporting “a lot” of 
cancer-related financial problems reporting a lower rate of lumpectomy as opposed to 
mastectomy (50.0% vs 75.0%). Treatment with chemotherapy (p=0.121), radiation 
(p=0.885), or trastuzumab (p=0.146) was not associated with cancer-related financial 
problems.  
 
The majority (n=61, 84.7%) self-reported their QOL to be “excellent”, “very good”, or 
“good”, while 6 (8.4%) answered “fair” or “poor”. Cancer-related financial problems 
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were associated with overall rating of QOL (p=0.004), as well as self-reported social 
QOL (p=0.004) (Table 9). Compared to patients reporting no cancer-related financial 
difficulty, a greater proportion of patients reporting “a lot” of cancer-related financial 
problems described their overall QOL as “poor” (7.7% vs. 0.0%). Cancer-related 
financial problems were also significantly associated with degree of self-reported worry 
that their cancer would return or get worse (p=0.003). A greater proportion of patients 
reporting “a lot” of cancer-related financial problems worried “all the time” that their 
cancer would return or get worse in comparison to patients reporting no financial 
problems (7.7% vs. 3.4%). The degree of cancer-related financial problems was not 
significantly associated with self-reported physical quality of life (p=0.095), mental 
quality of life (p=0.130), or belief that cancer would return or get worse (p=0.302). The 
proportion of patients reporting a quality of life of “good” or better by reported degree of 





As the cost of cancer care in the United States continues to increase and as the prevalence 
of cancer grows higher, the financial burden of a cancer diagnosis is becoming an 
increasingly important issue for cancer survivors. Cancer patients are especially 
vulnerable to economic hardship due to their disease, with evidence to suggest they face 
greater out-of-pocket health care expenses in comparison with patients suffering from 
other chronic diseases (15).  This effect can be long-lasting. Beyond the physical and 
psychosocial impact of a cancer diagnosis, financial problems due to cancer can 
negatively impact survivors’ quality of life.  
 
We analyzed results of a nationwide health interview study and found that the degree of 
cancer-related financial problems was the strongest independent predictor of quality of 
life among a population of cancer survivors over the age of 18. Patients reporting “a lot” 
of financial problems were about four times less likely to report a quality of life that was 
“good” or better (OR: 0.24; 95% CI 0.14-0.40) compared to patients reporting no 
financial problems. The magnitude of cancer-related financial difficulty was a more 
significant predictor of quality of life than age, education, race, and family income. These 
findings highlight the potentially powerful impact of financial strain on a patient’s 
perception of their overall well-being after a cancer diagnosis.  
 
Like others, we found that increased cancer-related financial hardship is associated with 
lower household income (33, 34), female gender (35), and younger age (33, 19, 34). 
Several factors can be identified to help explain the gender disparity. In comparison with 
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men, terminally ill women have been found to be less likely to receive caregiving 
assistance from family and friends and thus more likely to have to pay for nursing care 
(35). Additionally, women may be disproportionately affected by childcare expenses; 
these expenses may contribute to increased financial burden after a cancer diagnosis.  
 
Patients over the age of 65 reported fewer cancer-related financial problems. This is in 
accordance with findings by Shankaran et al, who noted that in a study of insured patients 
receiving adjuvant chemotherapy for colon cancer, younger age was associated with a 
greater degree of financial hardship independent of insurance status (34). Insurance status 
also plays a role, with patients covered by Medicare also reporting a lower degree of 
economic burden. Americans over 65 benefit from Medicare coverage, and are thus less 
likely than younger patients to be uninsured or underinsured, leading to increased 
financial protection from medical diagnoses requiring expensive treatment. Furthermore, 
older patients are more likely to have accrued financial resources and are less likely to 
have younger dependents.  
 
Several studies have reported that financial difficulties and low income are associated 
with anxiety and depression in cancer survivors (36, 37, 38, 39). However, few have 
examined the relationship between cancer-specific financial problems and quality of life. 
Using survey data from patients on a cancer registry in Ireland, Sharp et al. found that 
cancer-related financial strain was associated with a roughly three-fold risk for 
depression (29). Similarly, among a group of breast cancer survivors from the 
Southeastern United States, Meneses et al. reported an association between cancer-related 
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financial events, such as decrease in work productivity and additional incurred out of 
pocket expenses, with decreased quality of life (30). A major strength of our study is the 
use of the NHIS data, which is designed to be representative of the entire population of 
the US, thus limiting population biases that may be present in institution-based or 
regional studies. This study is, to our knowledge, the largest, most contemporary 
population-based analysis of the financial impact of cancer on the self-reported quality of 
life of Americans. 
 
We noted a relatively low proportion of patients claiming financial problems due to 
cancer in comparison to some prior studies. The majority of patients in our study (69.6%) 
claimed no financial problems at all, whereas much smaller proportions reported “a lot” 
(8.6%), or “some” (11.7%). Reported levels of cancer-related financial strain vary. For 
example, Sharp and colleagues found that 32% of patients more than 6 months post 
cancer diagnosis reported increased financial strain due to cancer (29). Similarly, we 
found that 30% of patients surveyed in our study reported some degree of cancer-related 
financial problems. However, Zafar et al. found that, even among a group of insured 
patients who did not request co-payment assistance, 85% reported at least some degree of 
financial burden from cancer-related expenses; for 27%, this burden was significant or 
catastrophic (19). Aspects of our study population may explain the lower reported rates of 
financial strain. The survey captured responses from patients who reported a diagnosis of 
cancer ever in their lifetime. Recall bias is likely to be present: patients for whom much 
time has elapsed since cancer diagnosis and treatment may be less likely to recall 
financial hardship, especially if they have reaccumulated resources lost during that time. 
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It is also possible that the survey population includes some patients who were diagnosed 
with childhood cancer and were thus, to a degree, protected from the financial toll due to 
their disease.  
 
Because the NHIS is a cross-sectional study, no conclusions about causation can be 
drawn. Additionally, the survey does not provide any data on cancer stage and prognosis. 
Patients with more advanced disease may be more likely to have increased worry, lower 
quality of life, and increased financial difficulties; we are unable to examine this 
relationship with the available survey data. Furthermore, the survey included any patients 
who had ever been told they had cancer, and no temporal relationship between cancer 
diagnosis and emergence of financial difficulty can thus be elucidated from the data. This 
temporal relationship is also likely to confound data on quality of life and degree of 
worry that cancer may return; for example, patients for whom more time has elapsed 
since a cancer diagnosis may be less likely to worry about recurrence. Finally, the data do 
not report on the sources of financial difficulties for cancer patients, which could inform 
the types of interventions necessary to address this problem.  
 
In order to address some of these limitations, we designed a cross-sectional survey study 
of breast cancer patients seen at the Breast Center – Smilow Cancer Hospital at Yale-
New Haven Hospital. To decrease the possibility of recall bias, as seen in the NHIS data, 
we surveyed only breast cancer patients who had received their diagnosis between 6 and 
18 months prior to survey administration. We found that, as seen in our analysis of data 
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from a population-based nationwide study, the degree to which cancer caused financial 
problems was significantly associated with poorer quality of life (p=0.004).  
 
We observed that 30.6% of patients in this study reported “a lot” or “some” financial 
problems due to cancer. This rate is higher than that seen in the NHIS data and is more 
aligned with the 32% of patients that Sharp et al. observed who reported financial distress 
6 months after a cancer diagnosis (29). Given that the majority of cancer-related cost of 
care to Medicare occurs in the first year after diagnosis (8), this finding is consistent with 
what would be expected in a population of patients 6-18 months post-diagnosis rather 
than the population of all cancer survivors captured by NHIS. As in the NHIS data, recall 
bias may contribute to this finding; patients with a newer cancer diagnosis may be more 
likely to self-report financial problems in comparison to patients who have had a 
diagnosis for a longer period of time. 
 
The patient population in the Breast Center differs demographically in some respects to 
the American population as a whole. In comparison to an estimated 16.7% of Americans 
who are uninsured (40), only 2% of patients in our study reported no insurance coverage. 
Family income was roughly aligned with that expected in New Haven County; 45.9% of 
patients in this study reported a family income of $75,000 or higher, whereas the median 
income for the county in which the breast center is located is $60,549 (40). No data was 
obtained on the places of residence of survey respondents.  
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As was seen in the NHIS study, insurance status was significantly associated with cancer-
related financial problems, with fewer Medicare patients reporting “a lot” of financial 
burden. Younger age, too, was a significant covariate as seen in the NHIS data and other 
studies (33, 34).  
 
The effect of family income on cancer-related financial problems has also been studied. 
Both Fortner et al and Shankaran et al found, similar to our NHIS findings, that income 
was a significant indicator of financial distress due to cancer (33, 34).   In the Breast 
Center data, this variable was also significantly associated (p=0.029). It is worthwhile to 
point out that 15.8% of patients with annual household incomes above $100,000 reported 
“a lot” or “some” financial problems due to cancer, indicating that moderate to high-
income families are vulnerable to significant disease-related expense.  Additionally, 
40.0% of patients with annual household incomes below $35,000 reported “a lot” of 
cancer-related financial problems, with an additional 15.0% reporting “some”.  Many of 
these patients likely qualify for “safety net” health insurance programs (e.g. Medicaid) 
intended to cover health expenses for low-income citizens. These relatively high rates of 
self-reported financial burden among low-income patients may be suggestive that such 
programs do not provide sufficient assistance to offset the financial toll of a cancer 
diagnosis.  
 
When examining clinical and pathologic variables associated with cancer-related 
financial problems, we found that fewer patients with ER-positive disease and with a 
history of treatment with endocrine therapy reported cancer-related financial problems. 
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These variables are linked as diagnosis and treatment, and evidence suggests that 
aromatase inhibitors are a cost-effective treatment (41). Although ER-positive disease 
portends a better prognosis, we did not find that other prognostic factors, including tumor 
size, node status, and lymphovascular invasion were significantly associated with 
financial problems, suggesting that perhaps this association is due in part to the low cost 
of therapy available to patients with this diagnosis. In addition, it is possible that these 
patients were less likely to receive chemotherapy and may have been more likely to be 
recipients of Medicare benefits. 
 
While a history of receiving chemotherapy was not on its own significantly associated 
with financial problems, we found that among patients who received systemic therapy 
(chemotherapy or trastuzumab) without endocrine therapy, 9 (64.3%) reported “a lot” of 
cancer-related financial problems. In contrast, no patient who received endocrine therapy 
either alone or in conjunction with systemic therapy reported “a lot” of financial 
problems. This data supports the hypothesis that patients with hormone receptor-negative 
disease are more vulnerable to financial burden. These patients have a poorer prognosis, 
are more likely to have a poorer functional status, and are more likely to undergo 
prolonged treatment regimens with systemic therapy.  
 
While the Breast Center portion of this study (Aim #2) provided valuable insights into the 
impact of clinicopathologic and treatment variables on financial distress in breast center 
patients and aimed to minimize recall bias, it was limited by the small magnitude of the 
sample size that reduces the number of statistically significant observations that can be 
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made. The population in our academic center is demographically different from the 
population of cancer patients at large, so results cannot be directly extrapolated to apply 
to the population as a whole. However, these results complement the nationally 
representative work done with the NHIS data in Aim #1. Finally, as with the NHIS data, 
this is a cross-sectional study and thus no inferences about causation can be made.  
 
Conclusions and Future Directions 
Our data highlight the need to draw increased attention toward the economic burden 
caused by a cancer diagnosis and the impact this burden may have on a patient’s overall 
well-being. In both aims of our study, consistent with findings in several prior studies, the 
degree to which cancer caused financial problems was significantly associated with 
decreased quality of life. Given this association, further attention toward interventions 
that may decrease the financial burden of a cancer diagnosis is warranted, especially for 
those most at risk of experiencing cancer-related financial problems. 
 
Interventions to address this problem may be enacted at either the individual or systemic 
level. There has been some research directed at examining the nature of the physician-
patient relationship and the patient’s experience of financial burden of disease. Bullock et 
al. examined patient’s attitudes toward discussing cost of care and found that while only a 
minority of oncologists reported feeling comfortable discussing costs of care with their 
patients, the majority of cancer patients wanted their oncologist to address these costs 
during their visit (42). This disparity between the expectations of patients and oncologists 
about communication regarding costs of care may be addressed by further education of 
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oncologists both on patient communication preferences as well as on specifics of 
treatment costs. Increased utilization of non-physician team members, such as social 
workers, who are knowledgeable about financial barriers to treatment, can also play an 
integral role by providing patients with up-to-date information and reducing physician 
workload.  
 
On a larger scale, systematic changes to the American health care system are likely to 
affect the cost of cancer care as the Affordable Care Act (ACA) becomes progressively 
implemented. We noted in the NHIS data that uninsured patients were significantly more 
likely to experience “a lot” of financial problems due to cancer. By some estimates, the 
ACA will lead to a decrease in uninsured adults by 70%, thus portending a potential 
decrease in the financial burden of cancer on an individual basis (43). However, this 
estimate is not agreed upon by all researchers, and estimates are fluid as more 
information becomes available about utilization of health insurance exchanges. 
Additionally, the ACA will require more people to purchase insurance or, alternatively, 
pay a fine; this increased degree of cost-sharing may impose an additional financial 
burden. 
 
Furthermore, continued research on methods to increase cost effectiveness on a systems 
level may lead to a decrease in the individual cancer patient’s financial burden. As Zafar 
and Abernethy point out in their editorial on the subject, the ACA may ultimately 
contribute to decreased costs by shifting Medicare reimbursements away from a fee-for-
service model and towards an encounter-based approach, thus incentivizing the use of 
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cost-effective treatment (44). However, expenditures on drug therapy continue to increase 
in oncology practice; increasing numbers of new, targeted therapeutic agents contribute 
to this phenomenon, in addition to the widespread use of drugs for off-label indications. 
One 2005 study estimated that up to 75% of drugs used in oncology are prescribed for 
off-label indications (45). Further research on the efficacy of drugs for off-label use may 
guide clinicians toward more cost-effective therapies. Incorporation of cost effectiveness 
considerations into the FDA drug approval process may also contribute to a decrease in 
this trend. 
 
In summary, we found that lack of insurance coverage and lower family income is 
strongly associated with the degree of cancer-related financial problems. Subsets of 
patients for particular cancer types may be particularly susceptible to financial problems; 
such patients include those breast cancer patients with hormone receptor-negative disease, 
who are more likely to be younger and receive chemotherapy. Additional interventions to 
decrease personal costs due to cancer in the United States are worthy of further study, 
especially as the ACA in implemented over the next several years. Cost-effectiveness 
research to meticulously appraise the cost versus benefit of cancer therapies is needed, 
along with an increasing awareness on the part of clinicians of the impact that cancer 
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Table 1: Demographic characteristics of informative responders vs. those refusing to 





“Don’t know” or 
refused to respond 
(%) 
P-value 
 % total sample  98.5 1.5  
Sex   0.219 
      Male 44.0 39.3  
      Female 56.0 60.6  
Race   0.450 
      White 90.6 90.4  
      Black 6.7 7.5  
      Asian 1.5 1.2  
      All other 
      races 
1.2 0.4  
Age (years)   0.696 
     18-64 53.2 54.8  
      >65 46.8 45.2  
Education   0.300 
Less than grade 
12 
12.5 17.6  
    High school 
graduate 
27.5 25.4  
  Some college/ 
Associate’s 
29.8 31.0  
Bachelor’s  16.8 16.3  
Master’s  9.1 7.0  
Professional/ 
Doctorate 
4.4 2.8  
Insurance status   0.851 
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     Medicare 51.0 51.1  
     Medicaid 3.7 5.6  
     Military 2.7 3.0  
     Private 36.6 34.4  
     Not covered 6.0 5.9  
Total combined 
family income 
  0.055 
$0-$34,999 35.2 45.5  
$35,000 
-$74,999 
33.0 30.5  
$75,000 
-$99,999 
12.5 8.7  
$100,000 and 
over 
19.3 15.3  
Region   0.450 
Northeast 17.1 22.9  
Midwest 25.0 23.7  
South 37.4 35.3  
West 20.5 18.1  
Cancer type   0.280 
Breast 88.1 11.9  
Cervical 93.1 6.9  
Colorectal 89.3 10.7  
Lung 90.1 9.9  
Lymphoma/ 
leukemia 
86.6 13.4  
Melanoma 91.0 9.0  
Ovarian 84.2 15.8  
Prostate 87.0 13.0  
  40 
Thyroid 94.7 5.3  
Uterine 94.5 5.5  







Table 2: Degree to which cancer caused financial problems by demographic 
characteristics in NHIS population 
 





“Not at all” 
(%) 
P-value 
 % total sample  8.6 11.7 10.3 69.6  
Sex     0.016 
      Male 36.5 40.9 53.6 44.1  
      Female 63.5 59.1 46.5 55.9  
Race     < 0.001 
      White 81.2 86.3 90.2 92.6  
      Black 13.6 9.8 8.4 5.1  
      Asian 2.7 2.7 1.4 1.1  
      All other 
      races 
2.5 1.1 0.0 1.2  
Age (years)     < 0.001 
     18-64 81.0 65.5 55.7 47.3  
      >65 19.0 34.5 44.3 52.7  
Education     0.002 
Less than grade 
12 
16.2 13.5 19.5 10.8  
    High school 
graduate 
37.3 26.7 24.5 26.8  
  Some college/ 
Associate’s 
27.7 32.5 30.2 29.5  
Bachelor’s  12.1 17.6 14.1 17.7  
Master’s  5.9 6.5 8.7 10.0  
Professional/ 
Doctorate 
0.8 3.3 3.1 5.1  
  42 
Insurance status     < 0.001 
     Medicare 32.9 44.6 50.3 54.4  
     Medicaid 8.4 2.6 4.3 3.2  
     Military 5.2 1.1 2.8 2.6  
     Private 37.7 43.5 37.3 35.3  
     Not covered 15.9 8.2 5.2 4.6  
Total combined 
family income 
    < 0.001 
$0-$34,999 51.6 36.7 38.0 32.4  
$35,000 
-$74,999 
29.5 33.6 34.8 33.1  
$75,000 
-$99,999 
11.4 15.4 11.9 12.3  
$100,000 and 
over 
7.8 14.3 15.3 22.2  
Region     0.390 
Northeast 15.4 13.4 15.9 18.0  
Midwest 19.4 28.9 27.6 24.7  
South 46.2 38.0 38.3 36.1  
West 18.9 19.3 18.2 21.1  
Cancer type     <0.001 
Breast 12.0 16.6 10.0 61.4  
Cervical 5.5 13.5 10.3 70.6  
Colorectal 11.5 14.3 11.6 62.6  
Lung 23.7 8.8 19.6 48.0  
Lymphoma/ 
leukemia 
11.9 27.6 10.8 49.7  
Melanoma 3.0 6.0 9.6 81.5  
Ovarian 25.3 16.8 6.5 51.4  
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Prostate 4.0 8.0 14.8 73.2  
Thyroid 30.6 10.8 5.5 53.1  
Uterine 6.5 11.9 9.4 72.3  




Table 3: Bivariate analysis of degree to which cancer caused financial problems and 
quality of life ratings in NHIS population 






“Not at all” 
(%) 
P-value 
Rating of general 
quality of life 
    <0.001 
    Excellent 13.1 25.4 26.5 34.1  
    Very good 18.2 29.7 31.0 35.1  
    Good 33.6 29.8 28.5 22.4  
    Fair 23.4 13.0 11.6 6.6  
    Poor 11.7 2.0 2.5 1.8  
Rating of physical 
health 
    <0.001 
    Excellent 6.1 11.8 10.6 16.0  
    Very good 11.2 26.4 27.0 34.0  
    Good 30.7 37.2 34.2 32.4  
    Fair 33.4 16.3 17.5 13.3  
    Poor 18.6 8.4 10.6 4.3  
Rating of mental 
health, including 
mood and ability to 
think 
    <0.001 
    Excellent 11.7 20.1 21.2 32.4  
    Very good 21.5 35.7 36.3 34.8  
    Good 35.9 30.2 34.9 23.8  
    Fair 22.6 12.0 4.5 7.2  
    Poor 8.3 2.1 3.2 1.8  
Rating of 
satisfaction with 
social activities and 
relationships 
    <0.001 
  45 
    Excellent 15.8 18.0 19.1 28.8  
    Very good 17.5 31.2 30.2 32.7  
    Good 37.4 35.6 34.7 28.7  
    Fair 17.6 11.6 10.0 6.2  
    Poor 11.8 3.6 6.0 3.6  
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      




Table 4: Bivariate analysis of degree to which cancer caused financial problems and 
ratings of worry in NHIS population 
 






“Not at all” 
(%) 
P-value 
Belief the chances 
of cancer returning/ 
becoming worse in 
10yr  
    <0.001 
    Very low 28.7 39.0 37.4 50.6  
    Fairly low 10.4 22.5 20.1 15.6  
    Moderate 29.2 25.6 22.4 22.4  
    Fairly high 15.0 6.9 9.2 6.7  
    Very high 16.7 6.0 10.9 4.6  
Frequency of worry 
that cancer may 
come back/get 
worse “all the time” 
    <0.001 
    Never 25.7 35.5 33.9 55.6  
    Rarely 15.9 23.1 29.9 24.4  
    Sometimes 25.3 28.2 19.2 15.1  
    Often 12.7 7.1 12.3 3.3  















Table 5:  Multivariate analysis: quality of life of at least “good” by degree to which 
cancer caused financial problems and demographic characteristics in NHIS population 
Variable  Adjusted OR (95% CI) P-value 
Degree to which cancer 
caused financial problems 
 <0.001 
     A lot 0.24 (0.14-0.40)  
     Some 0.57 (0.33-0.99)  
     A little 0.67 (0.41-1.08)  
     Not at all  Referent  
Sex  0.016 
    Male Referent  
    Female 1.54 (0.97-2.47)  
Race   
    White Referent  
    Black 0.97 (0.60-1.57)  
    Asian 0.40 (0.17-0.95)  
    All other races 0.62 (0.18-2.14)  
Age  <0.001 
    18-64 Referent  
    >65 2.17 (1.14-4.15)  
Education  0.002 
     Less than grade 12 Referent  
    High school graduate 1.10 (0.70-1.74)  
    Some college/ Associate’s 
degree 
2.09 (1.26-3.44)  
    Bachelor’s degree 3.16 (1.53-6.51)  
    Master’s degree 2.40 (1.08-5.30)  
    Professional degree/ 
    Doctorate 
4.50 (0.88-22.87)  
  48 
Insurance status  <0.001 
     Medicare 0.48 (0.23-1.02)  
     Medicaid 0.63 (0.30-1.32)  
     Military 0.53 (0.19-1.48)  
     Private 1.65 (0.81-3.36)  
     Not covered Referent  
Total combined family 
income 
 <0.001 
     $0-$34,999 Referent  
     $35,000-$74,999 2.24 (1.48-3.41)  
     $75,000-$99,999 1.84 (0.93-3.63)  
     $100,000 and over 2.24 (1.01-4.98)  
Cancer type  <0.001 
    Breast Referent  
    Cervical 0.97 (0.47-1.99)  
    Colorectal 0.90 (0.41-2.02)  
    Lung 0.38 (0.15-0.96)  
    Lymphoma/ leukemia 0.91 (0.42-1.95)  
    Melanoma 1.45 (0.53-3.97)  
    Ovarian 1.24 (0.25-6.12)  
    Prostate 1.53 (0.64-3.62)  
    Thyroid 0.67 (0.17-2.57)  
    Uterine 0.97 (0.47-2.01)  




Table 6: Sociodemographic characteristics, treatment history, and pathologic features of 
Yale Breast Center survey respondents 
 
 Number of respondents 
 (percentage total sample) 
Race  
Caucasian 54 (75.0) 
Black/African American 12 (16.7) 
Asian 2 (2.8) 
Other 4 (5.6) 
Marital status  
Married 34 (47.2) 
Widowed 9 (12.5) 
Divorced 15 (20.8) 
Separated 4 (5.6) 
Never married 7 (9.7) 
Living with partner 3 (4.2) 
Education  
Less than grade 12 4 (5.6) 
High school graduate 15 (20.8) 
Some college/associate’s degree 24 (33.3) 
Bachelor’s  10 (13.9) 
Master’s  14 (19.4) 
Professional/ doctorate 5 (6.9) 
Annual family income  
  50 
$0-$34,999 22 (30.6) 
$35,000-$74,999 16 (22.2) 
$75,000-$99,999 13 (18.1) 
$100,000+ 20 (27.8) 
No response 1 (1.4) 
Insurance  
Medicare 16 (22.2) 
Medicaid 9 (12.5) 
Private 42 (58.3) 
Military 1 (1.4) 
Not covered 2 (2.8) 
Out-of-pocket health-care related 
expenses over the past year  
 
$0-$500 22 (30.6) 
$500-$1,999 19 (26.4) 
$2,000-$2,999 9 (12.5) 
$3,000-$4,999 8 (11.1) 
$5,000+ 12 (16.7) 





Table 7: Treatment history and pathologic characteristics of Yale Breast Center patients 
 
 Number of respondents  
(percentage of total sample) 
Surgery type  
Lumpectomy/ partial mastectomy 44 (61.1) 
Conventional mastectomy with no 
reconstruction 
10 (13.9) 
Skin-sparing mastectomy with 
reconstruction 
15 (20.8) 
No response 3 (4.2) 
Chemotherapy received  
Yes 29 (40.3) 
No 41 (56.9) 
No response 2 (2.8) 
Radiation received  
Yes 44 (61.1) 
No 25 (34.7) 
No response 3 (4.2) 
Trastuzumab prescribed  
Yes 8 (11.1) 
No 60 (83.3) 
No response 4 (5.6) 
Tamoxifen prescribed  
Yes  16 (22.2) 
No 50 (69.4) 
No response 6 (8.3) 
Aromatase inhibitor prescribed  
Yes 29 (40.3) 
No 39 (54.2) 
No response 4 (5.6) 
  52 
Cancer type  
DCIS 24 (33.3) 
Infiltrating ductal 36 (50.0) 
Infiltrating lobular 8 (11.1) 
Other 4 (5.6) 
Grade  
1 11 (15.3) 
2 34 (47.2) 
3 20 (27.8) 
Data not available 7 (9.7) 
Nodes positive  
Yes 17 (23.6) 
No 39 (54.2) 
Data not available 16 (22.2) 
Her2/Neu FISH  
Positive 1 (1.4) 
Negative 33 (45.8) 
Equivocal 1 (1.4) 
Data not available 37 (51.4) 
Estrogen receptor  
Positive 42 (48.3) 
Negative 11 (15.3) 
Data not available 19 (26.4) 
Progesterone receptor  
Positive 40 (55.6) 
Negative 13 (18.1) 
Data not available 19 (26.4) 
Lymphovascular invasion  
Yes 9 (12.5) 
No 59 (81.9) 




Table 8: Degree to which cancer caused financial problems by demographic 
characteristics and pathologic features among Yale Breast Center survey respondents 
 
 “A lot” 




“A little” n 
(%) 
 
“Not at all” 
n (%) 
P-value 
 % total sample  13 (18.1) 9 (12.5) 13 (18.1) 32 (44.4)  
Race     0.150 
      White 8 (61.5) 7 (77.8) 11 (84.6) 24 (75.0)  
      Black 2 (15.4) 1 (11.1) 1 (7.7) 7 (21.9)  
      Asian 0  (0.0) 1 (11.1) 1 (7.7) 0 (0.0)  
      All other 
      races 
3 (23.1) 0 (0.0) 0 (0.0) 1 (3.1)  
Education     0.013 
Less than grade 12 1 (7.7) 0 (0.0) 0 (0.0) 3 (9.4)  
    High school graduate 4 (30.8) 4 (44.4) 3 (23.1) 2 (6.3)  
  Some college/ 
Associate’s 
     6 (46.2) 3 (33.3) 6 (46.2) 8 (25.0)  
Bachelor’s  2 (15.4) 1 (11.1) 2 (15.4) 5 (15.6)  
Master’s  0 (0.0) 1 (11.1) 0 (0.0) 11 (34.4)  
Professional/ 
Doctorate 
0 (0.0) 0 (0.0) 2 (15.4) 3 (9.4)  
Insurance status     0.029 
     Medicare 1 (8.3) 3 (33.3) 2 (16.7) 9 (28.1)  
     Medicaid 5 (41.7) 1 (11.1) 0 (0.0) 2 (6.3)  
     Military 4 (33.3) 4 (44.4) 10 (83.3) 21 (65.6)  
     Private 1 (8.3) 0 (0.0) 0 (0.0) 0 (0.0)  
     Not covered 1 (8.3) 1 (11.1) 0 (0.0) 0 (0.0)  
Marital status     0.218 
  54 
Married 4 (30.8) 3 (33.3) 6 (46.2) 20 (62.5)  
Widowed 1 (7.7) 1 (11.1) 3 (23.1) 3 (9.4)  
Divorced 3 (23.1) 3 (33.3) 4 (30.8) 4 (12.5)  
Separated 1 (7.7) 1 (11.1) 0 (0.0) 2 (6.3)  
Never married 3 (23.1) 0 (0.0) 0 (0.0) 3 (9.4)  
Living with partner 1 (7.7) 1 (11.1) 0 (0.0) 0 (0.0)  
Total combined family 
income 
    0.029 
$0-$34,999       8 (61.5) 3 (37.5) 4 (30.8) 5 (15.6)  
$35,000 
-$74,999 
4 (30.8) 1 (12.5) 1 (7.7) 9 (28.1)  
$75,000 
-$99,999 
0 (0.0) 2 (25.0) 4 (30.8) 6 (18.8)  
$100,000 and over 1 (7.7) 2 (25.0) 4 (30.8) 12 (37.5)  
Out-of-pocket 
spending 
    0.066 
$0-$500 3 (25.0) 2 (22.2) 2 (15.4) 13 (40.6)  
$500-$1,999 5 (41.7) 2 (22.2) 1 (7.7) 11 (34.4)  
$2,000-$2,999 0 (0.0) 2 (22.2) 3 (23.1) 3 (9.4)  
$3,000-$4,999 1 (8.3) 1 (11.1) 5 (38.5) 1 (3.1)  
$5,000 or more 3 (25.0) 2 (22.2) 2 (15.4) 4 (12.5)  
Surgery type      0.050 
Lumpectomy 6 (50.0) 4 (44.4) 10 (90.9) 24 (75.0)  
Mastectomy 6 (50.0) 5 (55.6) 1 (9.1) 8 (25.0)  
Treatment history     <0.001 
Chemotherapy only 9 (69.2) 2 (22.2) 2 (15.4) 1 (3.1)  
Endocrine therapy only 0 (0.0) 2 (22.2) 3 (23.1) 10 (31.3)  
Both 0 (0.0) 1 (11.1) 2 (15.4) 8 (25.0)  
  55 
Neither 4 (30.8) 4 (44.4) 6 (46.2) 12 (37.5)  
Radiation therapy     0.885 
Yes 8 (66.7) 5 (55.6) 8 (72.7) 21 (65.6)  
No 4 (33.3) 4 (44.4) 3 (27.3) 11 (34.4)  
Cancer type     0.235 
Non-invasive 6 (46.2) 5 (55.6) 3 (23.1) 8 (25.8)  
Invasive 7 (53.8) 4 (44.4) 10 (76.9) 23 (74.2)  
Grade     0.103 
1 0 (0.0) 0 (0.0) 4 (30.8) 7 (24.1)  
2 5 (50.0) 4 (50.0) 6 (46.2) 15 (51.7)  
3 5 (50.0) 4 (50.0) 3 (23.1) 7 (24.1)  
Node status     0.284 
Positive 5 (45.5) 3 (42.9) 4 (36.4) 4 (17.4)  
Negative 6 (54.5) 4 (57.1) 7 (63.6) 19 (82.6)  
Her2/Neu FISH     0.480 
Positive 5 (100.0) 3 (75.0) 5 (100.0) 17 (94.4)  
Negative 0 (0.0) 0 (0.0) 0 (0.0) 1 (5.6)  
Equivocal 0 (0.0) 1 (25.0) 0 (0.0) 0 (0.0)  
ER status     0.037 
Positive 4 (44.4) 5 (100.0) 8 (88.9) 21 (84.0)  
Negative 5 (55.6) 0 (0.0) 1 (11.1) 4 (16.0)  
PR status     0.150 
Positive 4 (44.4) 4 (80.0) 8 (88.9) 20 (80.0)  
Negative 5 (55.6) 1 (20.0) 1 (11.1) 5 (20.0)  
Lymphovascular 
invasion 
    0.787 
Present 1 (9.1) 1 (12.5) 3 (23.1) 4 (12.9)  
  56 
Absent 10 (90.9) 7 (87.5) 10 (76.9) 27 (87.1)  
Age (median, years) 45 51 61 66 p<0.001 
Tumor size (median, 
cm) 




Table 9: Bivariate analysis of degree to which cancer caused financial problems and 
quality of life ratings among Yale Breast Center survey respondents 
 




“A little”  
n (%) 
“Not at all” n 
(%) 
P-value 
Rating of general 
quality of life 
    0.004 
    Excellent    0 (0.0) 1 (11.1) 3 (23.1) 14 (43.8)  
    Very good 4 (30.8) 3 (33.3) 8 (61.5) 12 (37.5)  
    Good 6 (46.2) 2 (22.2) 2 (15.4) 6 (18.8)  
    Fair 2 (15.4) 2 (22.2) 0 (0.0) 0 (0.0)  
    Poor 1 (7.7) 1 (11.1) 0 (0.0) 0 (0.0)  
Rating of physical 
health 
    0.095 
    Excellent 0 (0.0) 1 (11.1) 2 (15.4) 8 (25.0)  
    Very good 2 (15.4) 3 (33.3) 7 (53.8) 12 (37.5)  
    Good 7 (53.8) 2 (22.2) 3 (23.1) 10 (31.3)  
    Fair 3 (23.1) 3 (33.3) 1 (7.7) 2 (6.3)  
    Poor 1 (7.7) 0 (0.0) 0 (0.0) 0 (0.0)  
Rating of mental 
health, including 
mood and ability to 
think 
    0.130 
    Excellent 0 (0.0) 1 (11.1) 2 (15.4) 11 (34.4)  
    Very good 6 (46.2) 2 (22.2) 6 (46.2) 10 (31.3)  
    Good 3 (23.1) 3 (33.3) 3 (23.1) 9 (28.1)  
    Fair 3 (23.1) 3 (33.3) 2 (15.4) 2 (6.3)  
    Poor 1 (7.7) 0 (0.0) 0 (0.0) 0 (0.0)  
Rating of 
satisfaction with 
social activities and 
            0.004 
  58 
relationships 
    Excellent 0 (0.0) 1 (11.1) 2 (15.4) 14 (43.8)  
    Very good 5 (38.5) 2 (22.2) 6 (46.2) 13 (40.6)  
    Good 5 (38.5) 2 (22.2) 4 (30.8) 5 (15.6)  
    Fair 2 (15.4) 3 (33.3) 1 (7.7) 0 (0.0)  
    Poor 1 (7.7) 1 (11.1) 0 (0.0) 0 (0.0)  
      
      
      
      
      




Figure 1: Patients reporting a quality of life of “good” or better by reported degree of 
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